Scott C. Kogan, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Scott C. Kogan, MD

Professor, Department of Laboratory Medicine, UCSF
Co-Director, Mouse Pathology Core Facility, UCSF Helen Diller Family Comprehensive Cancer Center

scott.kogan@ucsf.edu

Phone: (415) 514-1590 (voice)
Box 0100, UCSF
San Francisco, CA 94143-0100

View on UCSF Profiles

Cancer Center Membership

Program Member » Hematopoietic Malignancies

Education

Harvard College, Cambridge, MA, A.B., 1986, Biochemical Sciences
University of California San Francisco, M.D., 1991, Medicine
Laboratory Medicine Residency, UCSF, 1991-1993, Laboratory Medicine
Hematopathology Fellowship, UCSF, 1997-1998, Hematopathology


Professional Experience

  • 1984-1985
    Laboratory of Dr. David Calhoun, Mount Sinai Medical Center, New York City, NY.
  • 1985-1986
    Laboratory of Dr. Leonard Guarente, Massachusetts Institute of Technology, Cambridge, MA.
  • 1986-1991
    Laboratory of Dr. Jane Gitschier, Howard Hughes Medical Institute of California, UCSF
  • 1991-1992
    Resident, Department of Laboratory Medicine, UCSF
  • 1992-1993
    Chief Resident, Department of Laboratory Medicine, UCSF
  • 1993-1997
    Laboratory of Dr. J. Michael Bishop, G.W. Hooper Foundation, UCSF
  • 1997-1998
    Hematopathology Fellow, Department of Laboratory Medicine, UCSF
  • 1998-2003
    Assistant Professor In-Residence, Department of Laboratory Medicine, UCSF
  • 2003-2008
    Associate Professor In-Residence, Department of Laboratory Medicine, UCSF
  • 2008-present
    Professor, Department of Laboratory Medicine, UCSF
  • 2000-2004
    Chair, Hematopathology Subcommittee, Mouse Models of Human Cancer Consortium, NCI
  • 2001-present
    Co-director, Mouse Pathology Shared Resource, UCSF Comprehensive Cancer Center
  • 2004-2007
    Member Scientific Committee Clinical Laboratory Hematology, American Society of Hematology
  • 2008-2009
    Chair Scientific Committee Hematopathology & Clinical Laboratory Hematology, ASH

Honors & Awards

  • 1986
    Summa Cum Laude, Phi Beta Kappa
  • 1986
    Joseph L. Barrett Award for Teaching, Harvard University
  • 1993
    National Committee for Clinical Laboratory Standards, Honored Graduate Award
  • 1993
    UCSF Molecular Medicine Training Program
  • 1993
    American Cancer Society Physician Research Training Award
  • 1994
    Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physicians
  • 1997
    Burroughs Wellcome Fund Career Award
  • 2000
    32nd Edward Mallinckrodt Jr. Scholar Award
  • 2001
    Medical Student Teaching Award, Excellence for Small Group Instruction
  • 2002
    Department of Laboratory Medicine Resident Teaching Award
  • 2004
    Leukemia & Lymphoma Society Scholar Award
  • 2007
    Mentor Award, UCSF Department of Pediatrics

Selected Publications

  1. Gaillard C, Tokuyasu TA, Rosen G, Sotzen J, Vitaliano-Prunier A, Roy R, Passegué E, de Thé H, Figueroa ME, Kogan SC. Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation. Haematologica. 2015 Aug; 100(8):1064-75.
    View on PubMed
  2. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015 May 18.
    View on PubMed
  3. Brondfield S, Umesh S, Corella A, Zuber J, Rappaport AR, Gaillard C, Lowe SW, Goga A, Kogan SC. Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemother Pharmacol. 2015 May 9.
    View on PubMed
  4. Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat Genet. 2015 May; 47(5):539-43.
    View on PubMed
  5. Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014 Dec 18; 124(26):3947-55.
    View on PubMed
  6. Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014 May 12; 25(5):652-65.
    View on PubMed
  7. Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 8; 111(14):5319-24.
    View on PubMed
  8. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, LaBarge MA, You L, Kogan SC, Gray JW, Mao JH, Wei G. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014 Jan 15; 74(2):520-31.
    View on PubMed
  9. Tesio M, Oser GM, Baccelli I, Blanco-Bose W, Wu H, Göthert JR, Kogan SC, Trumpp A. Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilization. J Exp Med. 2013 Oct 21; 210(11):2337-49.
    View on PubMed
  10. Arteaga MF, Mikesch JH, Qiu J, Christensen J, Helin K, Kogan SC, Dong S, So CW. The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia. Cancer Cell. 2013 Mar 18; 23(3):376-89.
    View on PubMed
  11. Li M, Jones L, Gaillard C, Binnewies M, Ochoa R, Garcia E, Lam V, Wei G, Yang W, Lobe C, Hermiston M, Passegué E, Kogan SC. Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations. Leukemia. 2013 Jul; 27(7):1570-3.
    View on PubMed
  12. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013 Jan 2; 123(1):335-9.
    View on PubMed
  13. Omidvar N, Maunakea ML, Jones L, Sevcikova S, Yin B, Himmel KL, Tennant TR, Le Beau MM, Largaespada DA, Kogan SC. PML-RARa co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica. 2013 Mar; 98(3):424-7.
    View on PubMed
  14. Bagley BN, Keane TM, Maklakova VI, Marshall JG, Lester RA, Cancel MM, Paulsen AR, Bendzick LE, Been RA, Kogan SC, Cormier RT, Kendziorski C, Adams DJ, Collier LS. A dominantly acting murine allele of Mcm4 causes chromosomal abnormalities and promotes tumorigenesis. PLoS Genet. 2012; 8(11):e1003034.
    View on PubMed
  15. Choi G, Huang B, Pinarbasi E, Braunstein SE, Horvai AE, Kogan S, Bhatia S, Faddegon B, Nakamura JL. Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. Cancer Res. 2012 Dec 15; 72(24):6425-34.
    View on PubMed
  16. Bergerson RJ, Collier LS, Sarver AL, Been RA, Lugthart S, Diers MD, Zuber J, Rappaport AR, Nixon MJ, Silverstein KA, Fan D, Lamblin AF, Wolff L, Kersey JH, Delwel R, Lowe SW, O'Sullivan MG, Kogan SC, Adams DJ, Largaespada DA. An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model. Blood. 2012 May 10; 119(19):4512-23.
    View on PubMed
  17. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, Kogan SC, Lowe SW. Control of the senescence-associated secretory phenotype by NF-?B promotes senescence and enhances chemosensitivity. Genes Dev. 2011 Oct 15; 25(20):2125-36.
    View on PubMed
  18. Huang Y, Hou JK, Chen TT, Zhao XY, Yan ZW, Zhang J, Yang J, Kogan SC, Chen GQ. PML-RARa enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway. Autophagy. 2011 Oct; 7(10):1132-44.
    View on PubMed
  19. Wang X, Takagawa J, Lam VC, Haddad DJ, Tobler DL, Mok PY, Zhang Y, Clifford BT, Pinnamaneni K, Saini SA, Su R, Bartel MJ, Sievers RE, Carbone L, Kogan S, Yeghiazarians Y, Hermiston M, Springer ML. Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response. Sci Transl Med. 2011 Sep 14; 3(100):100ra90.
    View on PubMed
  20. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011 Oct 27; 478(7370):524-8.
    View on PubMed

Go to UCSF Profiles, powered by CTSI